OxSonics webinar hosted by OIC

The webinar features a 20-minute presentation showcasing the company and recent developments, as well as touching on the measures being taken to mitigate the effects of the COVID-19 pandemic. This was followed by a 10-minute Q&A session with CEO Colin Story and FD Chris Hill.

OxSonics was spun out from the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory at the University of Oxford in 2014 to develop ground-breaking ultrasound technology that uses proprietary Sono-Sensitive Particles (SSPs) to increase the tumour penetration of cancer drugs.

Important notice: This webinar recording is for information purposes only. Reliance on the information in this webinar recording, for the purpose of engaging in any investment activity, may expose an individual to a risk of losing all of the funds invested. The information disclosed in this webinar recording does not constitute, or should be considered as, an offer to buy or sell or solicitation of an offer to buy or sell any security or share.